<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd"><identifier identifierType="DOI">10.26249/FK2/NPX7DU</identifier><creators><creator><creatorName nameType="Personal">Pollmann, Christoph</creatorName><givenName>Christoph</givenName><familyName>Pollmann</familyName><nameIdentifier nameIdentifierScheme="ORCID">0000-0002-1473-0288</nameIdentifier><affiliation>Osnabrück University</affiliation></creator></creators><titles><title>A Strategy to Design Protein-based Antagonists Against Type I Cytokine Receptors</title></titles><publisher>osnaData</publisher><publicationYear>2024</publicationYear><subjects><subject>Medicine, Health and Life Sciences</subject></subjects><contributors><contributor contributorType="ContactPerson"><contributorName nameType="Personal">Pollmann, Christoph</contributorName><givenName>Christoph</givenName><familyName>Pollmann</familyName><affiliation>Osnabrück University</affiliation></contributor></contributors><dates><date dateType="Submitted">2024-08-30</date><date dateType="Updated">2024-08-30</date></dates><resourceType resourceTypeGeneral="Dataset"/><relatedIdentifiers><relatedIdentifier relationType="IsCitedBy" relatedIdentifierType="URL">https://omero.cellnanos.uni-osnabrueck.de/webclient/?show=project-15707</relatedIdentifier></relatedIdentifiers><version>1.0</version><rightsList><rights rightsURI="info:eu-repo/semantics/openAccess"/><rights rightsURI="https://creativecommons.org/publicdomain/zero/1.0/">CC0 Waiver</rights></rightsList><descriptions><description descriptionType="Abstract">Excessive cytokine signaling resulting from dysregulation of a cytokine or its receptor can be a main driver of cancer, autoimmune or hematopoietic disorders. Here we leverage protein design to create tailored cytokine receptor blockers with idealized properties. Specifically, we aimed to tackle the granulocyte-colony stimulating factor receptor (G-CSFR), a mediator of different types of leukemia and autoinflammatory diseases. By modifying designed G-CSFR binders, we engineered hyper-stable proteins that function as nanomolar signaling antagonists. X-ray crystallography showed atomic-level agreement with the experimental structure of an exemplary design. Furthermore, the most potent design blocks G-CSFR in acute myeloid leukemia cells and primary hematopoietic stem cells. Thus, the resulting designs can be used for inhibiting or homing to G-CSFR-expressing cells. Our work also demonstrates that designed cytokine mimics can be used to derive non-activating variants for tackling a range of cytokine receptors.</description></descriptions><geoLocations/></resource>